Table 3.
The correlation between clinical course of myositis and cancer
| Autoantibodies | Patients with paralleled clinical course, numbera | Patients with non-paralleled clinical course, number | Total numberb |
|---|---|---|---|
| Anti-TIF1-γ | 20 | 14 | 34 |
| Anti-NXP2 | 2 | 1 | 3 |
| Anti-SAE1 | 2 | 2 | 4 |
| Anti-HMGCR | 1 | 0 | 1 |
| Anti-SRP | 0 | 1 | 1 |
| Anti-Jo-1 | 1 | 4 | 5 |
| Anti-PL-7 | 0 | 1 | 1 |
| Anti-PL-12 | 1 | 2 | 3 |
| Anti-EJ | 0 | 1 | 1 |
| Anti-MDA5 | 0 | 1 | 1 |
| MSAs-c | 3 | 10 | 13 |
Abbreviations: MSAs myositis specific autoantibodies
aA paralleled clinical course meant that myositis emerged/deteriorated with the progression/recurrence of previously diagnosed cancers, cancer emerged with the recurrence of previously diagnosed IIMs, and/or myositis improved after removal or effective treatment of the cancer
bFour patients with anti-TIF1-γ and one MSA-negative patient were lost to follow up
cNegative for all of the listed MSAs